Global Bevacizumab Market Growth 2025-2031

December 2025 | 88 pages | ID: G5464DD6A866EN
LP Information

Abstracts

The global Bevacizumab market size is predicted to grow from US$ 66.6 million in 2025 to US$ 87.1 million in 2031; it is expected to grow at a CAGR of 4.6% from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

Bevacizumab, sold under the trade name Avastin, is a medication used to treat a number of types of cancers and a specific eye disease.

Bevacizumab is a monoclonal antibody used for the treatment of various types of cancer, including colorectal, lung, breast, and kidney cancers. The global market for bevacizumab is being driven by several factors. The global prevalence of cancer is on the rise, primarily due to factors such as aging population, lifestyle changes, and environmental factors. This has led to a higher demand for effective cancer therapies like bevacizumab. Bevacizumab is considered a targeted therapy as it selectively inhibits the growth of blood vessels that feed tumors, thereby suppressing tumor growth and progression. The growing preference for targeted therapies among healthcare providers and patients is driving the market for bevacizumab. Bevacizumab has received regulatory approvals for the treatment of various types of cancers, including advanced colorectal, non-small cell lung, metastatic breast, and renal cell carcinoma. The expanding list of approved indications is contributing to the market growth. Improvements in healthcare infrastructure, particularly in emerging markets, have increased access to advanced cancer therapies like bevacizumab. This has led to a wider patient pool and increased market demand. Governments and private entities are investing heavily in healthcare, including cancer treatment. This increased healthcare spending is supporting the availability and affordability of bevacizumab, driving market growth.

LP Information, Inc. (LPI) ' newest research report, the “Bevacizumab Industry Forecast” looks at past sales and reviews total world Bevacizumab sales in 2024, providing a comprehensive analysis by region and market sector of projected Bevacizumab sales for 2025 through 2031. With Bevacizumab sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Bevacizumab industry.

This Insight Report provides a comprehensive analysis of the global Bevacizumab landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Bevacizumab portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Bevacizumab market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Bevacizumab and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Bevacizumab.

This report presents a comprehensive overview, market shares, and growth opportunities of Bevacizumab market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• Avastin (bevacizumab)
• Mvasi (bevacizumab-awwb)

Segmentation by Application:

• Cancer
• Eye Diease

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• Genentech
• Amgen
• Aark Pharmaceuticals
• Beacon Pharmaceuticals Limited
• Balaji Medical Services Private Limited
• MVASI (bevacizumab)
• Mylan

Key Questions Addressed in this Report

What is the 10-year outlook for the global Bevacizumab market?

What factors are driving Bevacizumab market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Bevacizumab market opportunities vary by end market size?

How does Bevacizumab break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Bevacizumab Annual Sales 2020-2031
  2.1.2 World Current & Future Analysis for Bevacizumab by Geographic Region, 2020, 2024 & 2031
  2.1.3 World Current & Future Analysis for Bevacizumab by Country/Region, 2020, 2024 & 2031
2.2 Bevacizumab Segment by Type
  2.2.1 Avastin (bevacizumab)
  2.2.2 Mvasi (bevacizumab-awwb)
2.3 Bevacizumab Sales by Type
  2.3.1 Global Bevacizumab Sales Market Share by Type (2020-2025)
  2.3.2 Global Bevacizumab Revenue and Market Share by Type (2020-2025)
  2.3.3 Global Bevacizumab Sale Price by Type (2020-2025)
2.4 Bevacizumab Segment by Application
  2.4.1 Cancer
  2.4.2 Eye Diease
2.5 Bevacizumab Sales by Application
  2.5.1 Global Bevacizumab Sale Market Share by Application (2020-2025)
  2.5.2 Global Bevacizumab Revenue and Market Share by Application (2020-2025)
  2.5.3 Global Bevacizumab Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Bevacizumab Breakdown Data by Company
  3.1.1 Global Bevacizumab Annual Sales by Company (2020-2025)
  3.1.2 Global Bevacizumab Sales Market Share by Company (2020-2025)
3.2 Global Bevacizumab Annual Revenue by Company (2020-2025)
  3.2.1 Global Bevacizumab Revenue by Company (2020-2025)
  3.2.2 Global Bevacizumab Revenue Market Share by Company (2020-2025)
3.3 Global Bevacizumab Sale Price by Company
3.4 Key Manufacturers Bevacizumab Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Bevacizumab Product Location Distribution
  3.4.2 Players Bevacizumab Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR BEVACIZUMAB BY GEOGRAPHIC REGION

4.1 World Historic Bevacizumab Market Size by Geographic Region (2020-2025)
  4.1.1 Global Bevacizumab Annual Sales by Geographic Region (2020-2025)
  4.1.2 Global Bevacizumab Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Bevacizumab Market Size by Country/Region (2020-2025)
  4.2.1 Global Bevacizumab Annual Sales by Country/Region (2020-2025)
  4.2.2 Global Bevacizumab Annual Revenue by Country/Region (2020-2025)
4.3 Americas Bevacizumab Sales Growth
4.4 APAC Bevacizumab Sales Growth
4.5 Europe Bevacizumab Sales Growth
4.6 Middle East & Africa Bevacizumab Sales Growth

5 AMERICAS

5.1 Americas Bevacizumab Sales by Country
  5.1.1 Americas Bevacizumab Sales by Country (2020-2025)
  5.1.2 Americas Bevacizumab Revenue by Country (2020-2025)
5.2 Americas Bevacizumab Sales by Type (2020-2025)
5.3 Americas Bevacizumab Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Bevacizumab Sales by Region
  6.1.1 APAC Bevacizumab Sales by Region (2020-2025)
  6.1.2 APAC Bevacizumab Revenue by Region (2020-2025)
6.2 APAC Bevacizumab Sales by Type (2020-2025)
6.3 APAC Bevacizumab Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Bevacizumab by Country
  7.1.1 Europe Bevacizumab Sales by Country (2020-2025)
  7.1.2 Europe Bevacizumab Revenue by Country (2020-2025)
7.2 Europe Bevacizumab Sales by Type (2020-2025)
7.3 Europe Bevacizumab Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Bevacizumab by Country
  8.1.1 Middle East & Africa Bevacizumab Sales by Country (2020-2025)
  8.1.2 Middle East & Africa Bevacizumab Revenue by Country (2020-2025)
8.2 Middle East & Africa Bevacizumab Sales by Type (2020-2025)
8.3 Middle East & Africa Bevacizumab Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Bevacizumab
10.3 Manufacturing Process Analysis of Bevacizumab
10.4 Industry Chain Structure of Bevacizumab

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Bevacizumab Distributors
11.3 Bevacizumab Customer

12 WORLD FORECAST REVIEW FOR BEVACIZUMAB BY GEOGRAPHIC REGION

12.1 Global Bevacizumab Market Size Forecast by Region
  12.1.1 Global Bevacizumab Forecast by Region (2026-2031)
  12.1.2 Global Bevacizumab Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Bevacizumab Forecast by Type (2026-2031)
12.7 Global Bevacizumab Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Genentech
  13.1.1 Genentech Company Information
  13.1.2 Genentech Bevacizumab Product Portfolios and Specifications
  13.1.3 Genentech Bevacizumab Sales, Revenue, Price and Gross Margin (2020-2025)
  13.1.4 Genentech Main Business Overview
  13.1.5 Genentech Latest Developments
13.2 Amgen
  13.2.1 Amgen Company Information
  13.2.2 Amgen Bevacizumab Product Portfolios and Specifications
  13.2.3 Amgen Bevacizumab Sales, Revenue, Price and Gross Margin (2020-2025)
  13.2.4 Amgen Main Business Overview
  13.2.5 Amgen Latest Developments
13.3 Aark Pharmaceuticals
  13.3.1 Aark Pharmaceuticals Company Information
  13.3.2 Aark Pharmaceuticals Bevacizumab Product Portfolios and Specifications
  13.3.3 Aark Pharmaceuticals Bevacizumab Sales, Revenue, Price and Gross Margin (2020-2025)
  13.3.4 Aark Pharmaceuticals Main Business Overview
  13.3.5 Aark Pharmaceuticals Latest Developments
13.4 Beacon Pharmaceuticals Limited
  13.4.1 Beacon Pharmaceuticals Limited Company Information
  13.4.2 Beacon Pharmaceuticals Limited Bevacizumab Product Portfolios and Specifications
  13.4.3 Beacon Pharmaceuticals Limited Bevacizumab Sales, Revenue, Price and Gross Margin (2020-2025)
  13.4.4 Beacon Pharmaceuticals Limited Main Business Overview
  13.4.5 Beacon Pharmaceuticals Limited Latest Developments
13.5 Balaji Medical Services Private Limited
  13.5.1 Balaji Medical Services Private Limited Company Information
  13.5.2 Balaji Medical Services Private Limited Bevacizumab Product Portfolios and Specifications
  13.5.3 Balaji Medical Services Private Limited Bevacizumab Sales, Revenue, Price and Gross Margin (2020-2025)
  13.5.4 Balaji Medical Services Private Limited Main Business Overview
  13.5.5 Balaji Medical Services Private Limited Latest Developments
13.6 MVASI (bevacizumab)
  13.6.1 MVASI (bevacizumab) Company Information
  13.6.2 MVASI (bevacizumab) Bevacizumab Product Portfolios and Specifications
  13.6.3 MVASI (bevacizumab) Bevacizumab Sales, Revenue, Price and Gross Margin (2020-2025)
  13.6.4 MVASI (bevacizumab) Main Business Overview
  13.6.5 MVASI (bevacizumab) Latest Developments
13.7 Mylan
  13.7.1 Mylan Company Information
  13.7.2 Mylan Bevacizumab Product Portfolios and Specifications
  13.7.3 Mylan Bevacizumab Sales, Revenue, Price and Gross Margin (2020-2025)
  13.7.4 Mylan Main Business Overview
  13.7.5 Mylan Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Bevacizumab Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Bevacizumab Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Avastin (bevacizumab)
Table 4. Major Players of Mvasi (bevacizumab-awwb)
Table 5. Global Bevacizumab Sales by Type (2020-2025) & (K Units)
Table 6. Global Bevacizumab Sales Market Share by Type (2020-2025)
Table 7. Global Bevacizumab Revenue by Type (2020-2025) & ($ million)
Table 8. Global Bevacizumab Revenue Market Share by Type (2020-2025)
Table 9. Global Bevacizumab Sale Price by Type (2020-2025) & (USD/Unit)
Table 10. Global Bevacizumab Sale by Application (2020-2025) & (K Units)
Table 11. Global Bevacizumab Sale Market Share by Application (2020-2025)
Table 12. Global Bevacizumab Revenue by Application (2020-2025) & ($ million)
Table 13. Global Bevacizumab Revenue Market Share by Application (2020-2025)
Table 14. Global Bevacizumab Sale Price by Application (2020-2025) & (USD/Unit)
Table 15. Global Bevacizumab Sales by Company (2020-2025) & (K Units)
Table 16. Global Bevacizumab Sales Market Share by Company (2020-2025)
Table 17. Global Bevacizumab Revenue by Company (2020-2025) & ($ millions)
Table 18. Global Bevacizumab Revenue Market Share by Company (2020-2025)
Table 19. Global Bevacizumab Sale Price by Company (2020-2025) & (USD/Unit)
Table 20. Key Manufacturers Bevacizumab Producing Area Distribution and Sales Area
Table 21. Players Bevacizumab Products Offered
Table 22. Bevacizumab Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Bevacizumab Sales by Geographic Region (2020-2025) & (K Units)
Table 26. Global Bevacizumab Sales Market Share Geographic Region (2020-2025)
Table 27. Global Bevacizumab Revenue by Geographic Region (2020-2025) & ($ millions)
Table 28. Global Bevacizumab Revenue Market Share by Geographic Region (2020-2025)
Table 29. Global Bevacizumab Sales by Country/Region (2020-2025) & (K Units)
Table 30. Global Bevacizumab Sales Market Share by Country/Region (2020-2025)
Table 31. Global Bevacizumab Revenue by Country/Region (2020-2025) & ($ millions)
Table 32. Global Bevacizumab Revenue Market Share by Country/Region (2020-2025)
Table 33. Americas Bevacizumab Sales by Country (2020-2025) & (K Units)
Table 34. Americas Bevacizumab Sales Market Share by Country (2020-2025)
Table 35. Americas Bevacizumab Revenue by Country (2020-2025) & ($ millions)
Table 36. Americas Bevacizumab Sales by Type (2020-2025) & (K Units)
Table 37. Americas Bevacizumab Sales by Application (2020-2025) & (K Units)
Table 38. APAC Bevacizumab Sales by Region (2020-2025) & (K Units)
Table 39. APAC Bevacizumab Sales Market Share by Region (2020-2025)
Table 40. APAC Bevacizumab Revenue by Region (2020-2025) & ($ millions)
Table 41. APAC Bevacizumab Sales by Type (2020-2025) & (K Units)
Table 42. APAC Bevacizumab Sales by Application (2020-2025) & (K Units)
Table 43. Europe Bevacizumab Sales by Country (2020-2025) & (K Units)
Table 44. Europe Bevacizumab Revenue by Country (2020-2025) & ($ millions)
Table 45. Europe Bevacizumab Sales by Type (2020-2025) & (K Units)
Table 46. Europe Bevacizumab Sales by Application (2020-2025) & (K Units)
Table 47. Middle East & Africa Bevacizumab Sales by Country (2020-2025) & (K Units)
Table 48. Middle East & Africa Bevacizumab Revenue Market Share by Country (2020-2025)
Table 49. Middle East & Africa Bevacizumab Sales by Type (2020-2025) & (K Units)
Table 50. Middle East & Africa Bevacizumab Sales by Application (2020-2025) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Bevacizumab
Table 52. Key Market Challenges & Risks of Bevacizumab
Table 53. Key Industry Trends of Bevacizumab
Table 54. Bevacizumab Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Bevacizumab Distributors List
Table 57. Bevacizumab Customer List
Table 58. Global Bevacizumab Sales Forecast by Region (2026-2031) & (K Units)
Table 59. Global Bevacizumab Revenue Forecast by Region (2026-2031) & ($ millions)
Table 60. Americas Bevacizumab Sales Forecast by Country (2026-2031) & (K Units)
Table 61. Americas Bevacizumab Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 62. APAC Bevacizumab Sales Forecast by Region (2026-2031) & (K Units)
Table 63. APAC Bevacizumab Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 64. Europe Bevacizumab Sales Forecast by Country (2026-2031) & (K Units)
Table 65. Europe Bevacizumab Revenue Forecast by Country (2026-2031) & ($ millions)
Table 66. Middle East & Africa Bevacizumab Sales Forecast by Country (2026-2031) & (K Units)
Table 67. Middle East & Africa Bevacizumab Revenue Forecast by Country (2026-2031) & ($ millions)
Table 68. Global Bevacizumab Sales Forecast by Type (2026-2031) & (K Units)
Table 69. Global Bevacizumab Revenue Forecast by Type (2026-2031) & ($ millions)
Table 70. Global Bevacizumab Sales Forecast by Application (2026-2031) & (K Units)
Table 71. Global Bevacizumab Revenue Forecast by Application (2026-2031) & ($ millions)
Table 72. Genentech Basic Information, Bevacizumab Manufacturing Base, Sales Area and Its Competitors
Table 73. Genentech Bevacizumab Product Portfolios and Specifications
Table 74. Genentech Bevacizumab Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 75. Genentech Main Business
Table 76. Genentech Latest Developments
Table 77. Amgen Basic Information, Bevacizumab Manufacturing Base, Sales Area and Its Competitors
Table 78. Amgen Bevacizumab Product Portfolios and Specifications
Table 79. Amgen Bevacizumab Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 80. Amgen Main Business
Table 81. Amgen Latest Developments
Table 82. Aark Pharmaceuticals Basic Information, Bevacizumab Manufacturing Base, Sales Area and Its Competitors
Table 83. Aark Pharmaceuticals Bevacizumab Product Portfolios and Specifications
Table 84. Aark Pharmaceuticals Bevacizumab Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 85. Aark Pharmaceuticals Main Business
Table 86. Aark Pharmaceuticals Latest Developments
Table 87. Beacon Pharmaceuticals Limited Basic Information, Bevacizumab Manufacturing Base, Sales Area and Its Competitors
Table 88. Beacon Pharmaceuticals Limited Bevacizumab Product Portfolios and Specifications
Table 89. Beacon Pharmaceuticals Limited Bevacizumab Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 90. Beacon Pharmaceuticals Limited Main Business
Table 91. Beacon Pharmaceuticals Limited Latest Developments
Table 92. Balaji Medical Services Private Limited Basic Information, Bevacizumab Manufacturing Base, Sales Area and Its Competitors
Table 93. Balaji Medical Services Private Limited Bevacizumab Product Portfolios and Specifications
Table 94. Balaji Medical Services Private Limited Bevacizumab Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 95. Balaji Medical Services Private Limited Main Business
Table 96. Balaji Medical Services Private Limited Latest Developments
Table 97. MVASI (bevacizumab) Basic Information, Bevacizumab Manufacturing Base, Sales Area and Its Competitors
Table 98. MVASI (bevacizumab) Bevacizumab Product Portfolios and Specifications
Table 99. MVASI (bevacizumab) Bevacizumab Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 100. MVASI (bevacizumab) Main Business
Table 101. MVASI (bevacizumab) Latest Developments
Table 102. Mylan Basic Information, Bevacizumab Manufacturing Base, Sales Area and Its Competitors
Table 103. Mylan Bevacizumab Product Portfolios and Specifications
Table 104. Mylan Bevacizumab Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 105. Mylan Main Business
Table 106. Mylan Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Bevacizumab
Figure 2. Bevacizumab Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Bevacizumab Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Bevacizumab Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Bevacizumab Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Bevacizumab Sales Market Share by Country/Region (2024)
Figure 10. Bevacizumab Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Avastin (bevacizumab)
Figure 12. Product Picture of Mvasi (bevacizumab-awwb)
Figure 13. Global Bevacizumab Sales Market Share by Type in 2025
Figure 14. Global Bevacizumab Revenue Market Share by Type (2020-2025)
Figure 15. Bevacizumab Consumed in Cancer
Figure 16. Global Bevacizumab Market: Cancer (2020-2025) & (K Units)
Figure 17. Bevacizumab Consumed in Eye Diease
Figure 18. Global Bevacizumab Market: Eye Diease (2020-2025) & (K Units)
Figure 19. Global Bevacizumab Sale Market Share by Application (2024)
Figure 20. Global Bevacizumab Revenue Market Share by Application in 2025
Figure 21. Bevacizumab Sales by Company in 2025 (K Units)
Figure 22. Global Bevacizumab Sales Market Share by Company in 2025
Figure 23. Bevacizumab Revenue by Company in 2025 ($ millions)
Figure 24. Global Bevacizumab Revenue Market Share by Company in 2025
Figure 25. Global Bevacizumab Sales Market Share by Geographic Region (2020-2025)
Figure 26. Global Bevacizumab Revenue Market Share by Geographic Region in 2025
Figure 27. Americas Bevacizumab Sales 2020-2025 (K Units)
Figure 28. Americas Bevacizumab Revenue 2020-2025 ($ millions)
Figure 29. APAC Bevacizumab Sales 2020-2025 (K Units)
Figure 30. APAC Bevacizumab Revenue 2020-2025 ($ millions)
Figure 31. Europe Bevacizumab Sales 2020-2025 (K Units)
Figure 32. Europe Bevacizumab Revenue 2020-2025 ($ millions)
Figure 33. Middle East & Africa Bevacizumab Sales 2020-2025 (K Units)
Figure 34. Middle East & Africa Bevacizumab Revenue 2020-2025 ($ millions)
Figure 35. Americas Bevacizumab Sales Market Share by Country in 2025
Figure 36. Americas Bevacizumab Revenue Market Share by Country (2020-2025)
Figure 37. Americas Bevacizumab Sales Market Share by Type (2020-2025)
Figure 38. Americas Bevacizumab Sales Market Share by Application (2020-2025)
Figure 39. United States Bevacizumab Revenue Growth 2020-2025 ($ millions)
Figure 40. Canada Bevacizumab Revenue Growth 2020-2025 ($ millions)
Figure 41. Mexico Bevacizumab Revenue Growth 2020-2025 ($ millions)
Figure 42. Brazil Bevacizumab Revenue Growth 2020-2025 ($ millions)
Figure 43. APAC Bevacizumab Sales Market Share by Region in 2025
Figure 44. APAC Bevacizumab Revenue Market Share by Region (2020-2025)
Figure 45. APAC Bevacizumab Sales Market Share by Type (2020-2025)
Figure 46. APAC Bevacizumab Sales Market Share by Application (2020-2025)
Figure 47. China Bevacizumab Revenue Growth 2020-2025 ($ millions)
Figure 48. Japan Bevacizumab Revenue Growth 2020-2025 ($ millions)
Figure 49. South Korea Bevacizumab Revenue Growth 2020-2025 ($ millions)
Figure 50. Southeast Asia Bevacizumab Revenue Growth 2020-2025 ($ millions)
Figure 51. India Bevacizumab Revenue Growth 2020-2025 ($ millions)
Figure 52. Australia Bevacizumab Revenue Growth 2020-2025 ($ millions)
Figure 53. China Taiwan Bevacizumab Revenue Growth 2020-2025 ($ millions)
Figure 54. Europe Bevacizumab Sales Market Share by Country in 2025
Figure 55. Europe Bevacizumab Revenue Market Share by Country (2020-2025)
Figure 56. Europe Bevacizumab Sales Market Share by Type (2020-2025)
Figure 57. Europe Bevacizumab Sales Market Share by Application (2020-2025)
Figure 58. Germany Bevacizumab Revenue Growth 2020-2025 ($ millions)
Figure 59. France Bevacizumab Revenue Growth 2020-2025 ($ millions)
Figure 60. UK Bevacizumab Revenue Growth 2020-2025 ($ millions)
Figure 61. Italy Bevacizumab Revenue Growth 2020-2025 ($ millions)
Figure 62. Russia Bevacizumab Revenue Growth 2020-2025 ($ millions)
Figure 63. Middle East & Africa Bevacizumab Sales Market Share by Country (2020-2025)
Figure 64. Middle East & Africa Bevacizumab Sales Market Share by Type (2020-2025)
Figure 65. Middle East & Africa Bevacizumab Sales Market Share by Application (2020-2025)
Figure 66. Egypt Bevacizumab Revenue Growth 2020-2025 ($ millions)
Figure 67. South Africa Bevacizumab Revenue Growth 2020-2025 ($ millions)
Figure 68. Israel Bevacizumab Revenue Growth 2020-2025 ($ millions)
Figure 69. Turkey Bevacizumab Revenue Growth 2020-2025 ($ millions)
Figure 70. GCC Countries Bevacizumab Revenue Growth 2020-2025 ($ millions)
Figure 71. Manufacturing Cost Structure Analysis of Bevacizumab in 2025
Figure 72. Manufacturing Process Analysis of Bevacizumab
Figure 73. Industry Chain Structure of Bevacizumab
Figure 74. Channels of Distribution
Figure 75. Global Bevacizumab Sales Market Forecast by Region (2026-2031)
Figure 76. Global Bevacizumab Revenue Market Share Forecast by Region (2026-2031)
Figure 77. Global Bevacizumab Sales Market Share Forecast by Type (2026-2031)
Figure 78. Global Bevacizumab Revenue Market Share Forecast by Type (2026-2031)
Figure 79. Global Bevacizumab Sales Market Share Forecast by Application (2026-2031)
Figure 80. Global Bevacizumab Revenue Market Share Forecast by Application (2026-2031)